<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01876290</url>
  </required_header>
  <id_info>
    <org_study_id>2012/14</org_study_id>
    <secondary_id>2012-001486-32</secondary_id>
    <nct_id>NCT01876290</nct_id>
  </id_info>
  <brief_title>Dexamethasone and Ondansetron Versus Placebo for Postoperative Nausea and Vomiting</brief_title>
  <acronym>Loop-NVPO</acronym>
  <official_title>Should we Associate Dexamethasone and Ondansetron to Closed-loop Anesthesia to Reduce the Incidence of Postoperative Nausea and Vomiting After Bariatric Surgery?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Foch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Foch</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to test if it is indicated to associate dexamethasone and ondansetron&#xD;
      in obese patients having bariatric surgery under total intra-venous closed-loop anesthesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obese patients having bariatric surgery have frequently postoperative nausea and vomiting&#xD;
      (PONV). We want to test if it is indicated to associate dexamethasone and ondansetron in&#xD;
      obese patients having bariatric surgery under total intra-venous closed-loop anesthesia.&#xD;
&#xD;
      Two groups to be studied: one will receive 4 mg dexamethasone at the end of the anesthetic&#xD;
      induction and 4 mg ondansetron at the end of the surgical procedure, one will receive normal&#xD;
      saline.&#xD;
&#xD;
      One hundred twenty consecutive patients meeting the inclusion and exclusion criteria and who&#xD;
      give written informed consent to participate in the study will be randomly assigned to one of&#xD;
      two experimental groups using a 1:1 ratio.&#xD;
&#xD;
      Patients will be continuously monitored in the post anesthesia care unit (PACU) and the&#xD;
      medical floor for a total of 24 hours post operatively. Episodes of nausea, vomiting and&#xD;
      administration of rescue therapy for either nausea or vomiting will be recorded and time&#xD;
      stamped. In addition, severity of nausea will be evaluated by the patient using a standard&#xD;
      verbal response scale (VRS) ranging from 0-10, 0 being no nausea and 10 being severe nausea.&#xD;
      Rescue therapy for PONV episodes will consist of 4 mg ondansetron followed by 0.625 mg&#xD;
      droperidol if necessary.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative nausea or vomiting</measure>
    <time_frame>24 hours</time_frame>
    <description>Severe nausea (&gt; to 4 on a 0-10 visual analogue scale) or vomiting</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of nausea</measure>
    <time_frame>one day after anesthesia</time_frame>
    <description>incidence of nausea with delay of occurrence and severity (0-10 visual analogue scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of vomiting</measure>
    <time_frame>one day after anesthesia</time_frame>
    <description>incidence of vomiting with delay of occurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rescue treatment</measure>
    <time_frame>one day after anesthesia</time_frame>
    <description>use of rescue treatment for PONV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain</measure>
    <time_frame>one day after anesthesia</time_frame>
    <description>postoperative pain score (0-10 visual analogue scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sedation</measure>
    <time_frame>one day after surgery</time_frame>
    <description>postoperative sedation (0-10 visual analogue scale)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Dexamethasone and Ondansetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive Dexamethasone and Ondansetron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each patient will receive placebo instead of Dexamethasone and Ondansetron</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone and Ondansetron</intervention_name>
    <description>Comparison between Dexamethasone and Ondansetron and placebo in the prevention of postoperative Nausea and Vomiting</description>
    <arm_group_label>Dexamethasone and Ondansetron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients aged 18-75 years&#xD;
&#xD;
          -  Scheduled for bariatric surgery under total intra-venous closed-loop anesthesia&#xD;
&#xD;
          -  Apfel score equal or greater than 2&#xD;
&#xD;
          -  Consenting to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant, breast feeding women&#xD;
&#xD;
          -  Allergy&#xD;
&#xD;
          -  Contraindication to dexamethasone&#xD;
&#xD;
          -  Contraindication to ondansetron&#xD;
&#xD;
          -  Contraindication to propofol, remifentanil, morphine, ketoprofen&#xD;
&#xD;
          -  Limit to the use of bispectral index&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Fischler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Foch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique de la Baie des Citrons</name>
      <address>
        <city>Nouméa</city>
        <zip>98800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Liu N, Chazot T, Hamada S, Landais A, Boichut N, Dussaussoy C, Trillat B, Beydon L, Samain E, Sessler DI, Fischler M. Closed-loop coadministration of propofol and remifentanil guided by bispectral index: a randomized multicenter study. Anesth Analg. 2011 Mar;112(3):546-57. doi: 10.1213/ANE.0b013e318205680b. Epub 2011 Jan 13.</citation>
    <PMID>21233500</PMID>
  </reference>
  <reference>
    <citation>Song JW, Park EY, Lee JG, Park YS, Kang BC, Shim YH. The effect of combining dexamethasone with ondansetron for nausea and vomiting associated with fentanyl-based intravenous patient-controlled analgesia. Anaesthesia. 2011 Apr;66(4):263-7. doi: 10.1111/j.1365-2044.2011.06648.x.</citation>
    <PMID>21401538</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>May 29, 2013</study_first_submitted>
  <study_first_submitted_qc>June 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2013</study_first_posted>
  <last_update_submitted>October 28, 2016</last_update_submitted>
  <last_update_submitted_qc>October 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anesthesiology</keyword>
  <keyword>Complications</keyword>
  <keyword>Closed-loop</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

